Krystal Biotech, Inc. KRYS Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $9.11M.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s total debt?
- Krystal Biotech, Inc. (KRYS) reported total debt of $9.11M in Q1 2026.
- How has Krystal Biotech, Inc.'s total debt changed year-over-year?
- Krystal Biotech, Inc.'s total debt decreased by 5.7% year-over-year, from $9.66M to $9.11M.
- What is the long-term trend for Krystal Biotech, Inc.'s total debt?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s total debt has grown at a 18.8% compound annual growth rate (CAGR), from $3.95M to $9.34M.
- What does total debt mean?
- The total amount of money a company owes to lenders and creditors through loans, bonds, and leases.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and increased interest expense, which may heighten insolvency risk if not matched by revenue growth. A decrease indicates deleveraging, potentially improving the balance sheet's health and reducing interest burden.
- How does total debt compare across companies?
- Biotechnology companies in the development stage often maintain low debt levels to avoid interest burdens before commercialization, whereas mature peers may utilize debt to finance infrastructure and commercial scaling.